Consequently, AD progression can be ameliorated by limiting serotonin receptor functioning through the use of agonists for 5-HT4, 5-HT2A/2C and antagonists of 5-HT6, 5-HT1A or 5-HT3 and 5-HT1B [178]. This evidence concerns the gene HTR2A and Alzheimer disease.